secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001835268-25-000033
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect Biopharma Q1 net loss $10.3M; cash $84M; initiates two Phase 2 rademikibart trials
--------------------------------------------------------------------------------

- Cash, equivalents and ST investments $84.0M as of March 31, 2025; runway into 2027.
- Net loss $10.3M ($0.19/share) vs $8.7M ($0.16) in Q1 2024; R&D expense $6.6M, down $2.1M YoY.
- Initiated Phase 2 Seabreeze STAT asthma and COPD studies for rademikibart; topline data expected 1H 2026.
- Phase 2 data published in AJRCCM showed 420 mL FEV1 improvement vs placebo in eosinophilic asthma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000033/0001835268-25-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000033/cntb-20250515.htm
  HTML page:      https://secwatch.observer/filing/0001835268-25-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer